The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells

Stem Cell Research

Volumn 15, Issue 3, 2015, Pages 530-541

  Reikvam, Håkon ^a,b   Brenner, Annette K ^a   Hagen, Karen Marie ^a   Liseth, Knut ^b   Skrede, Silje ^a,b   Hatfield, Kimberley Joanne ^a   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myeloid leukemia; Chemokines; Cytokines; Gene expression; Mesenchymal stem cells; NF B; Toll like receptors

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CARBON TETRACHLORIDE; CXCL1 CHEMOKINE; CYTOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE A; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CHEMOKINE; TRANSCRIPTOME;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL PROLIFERATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEUKEMIA CELL; MALE; MESENCHYMAL STEM CELL; MESENCHYME CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; BONE MARROW CELL; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM;

CELL PROLIFERATION; CHEMOKINES; CYTOKINES; HUMANS; MESENCHYMAL STROMAL CELLS; MYELOID CELLS; TOLL-LIKE RECEPTORS; TRANSCRIPTOME;

EID: 84944235047     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2015.09.008     Document Type: Article

References (40)

1. Abdulkhalek S., Guo M., Amith S.R., Jayanth P., Szewczuk M.R. G-protein coupled receptor agonists mediate Neu1 sialidase and matrix metalloproteinase-9 cross-talk to induce transactivation of TOLL-like receptors and cellular signaling. Cell. Signal. 2012, 24:2035-2042.
2. Blau O., Baldus C.D., Hofmann W.K., Thiel G., Nolte F., Burmeister T., Turkmen S., Benlasfer O., Schumann E., Sindram A., Molkentin M., Mundlos S., Keilholz U., Thiel E., Blau I.W. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts. Blood 2011, 118:5583-5592.
3. Blau O., Hofmann W.K., Baldus C.D., Thiel G., Serbent V., Schumann E., Thiel E., Blau I.W. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. Exp. Hematol. 2007, 35:221-229.
4. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
5. Bruserud O., Gjertsen B.T., von Volkman H.L. In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J. Hematother. Stem Cell Res. 2000, 9:923-932.
6. Bruserud O., Ryningen A., Olsnes A.M., Stordrange L., Oyan A.M., Kalland K.H., Gjertsen B.T. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica 2007, 92:332-341.
7. Bruserud O., Ryningen A., Wergeland L., Glenjen N.I., Gjertsen B.T. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 2004, 89:391-402.
8. Bruserud Ø., Hovland R., Wergeland L., Huang T.S., Gjertsen B.T. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003, 88:416-428.
9. Döhner H., Estey E.H., Amadori S., Appelbaum F.R., Buchner T., Burnett A.K., Dombret H., Fenaux P., Grimwade D., Larson R.A., Lo-Coco F., Naoe T., Niederwieser D., Ossenkoppele G.J., Sanz M.A., Sierra J., Tallman M.S., Lowenberg B., Bloomfield C.D. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474.
10. Fellenberg K., Hauser N.C., Brors B., Neutzner A., Hoheisel J.D., Vingron M. Correspondence analysis applied to microarray data. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10781-10786.
11. Glenjen N., Mosevoll K.A., Bruserud O. Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia. Int. J. Cancer 2002, 101:86-94.
12. Hatfield K., Oyan A.M., Ersvaer E., Kalland K.H., Lassalle P., Gjertsen B.T., Bruserud O. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. Br. J. Haematol. 2009, 144:53-68.
13. Hatfield K., Ryningen A., Corbascio M., Bruserud O. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int. J. Cancer 2006, 119:2313-2321.
14. Huntly B.J., Gilliland D.G. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat. Rev. Cancer 2005, 5:311-321.
15. Ito S., Barrett A.J., Dutra A., Pak E., Miner S., Keyvanfar K., Hensel N.F., Rezvani K., Muranski P., Liu P., Melenhorst J.J., Larochelle A. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res. 2014, 14:95-104.
16. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E., Keene C.D., Ortiz-Gonzalez X.R., Reyes M., Lenvik T., Lund T., Blackstad M., Du J., Aldrich S., Lisberg A., Low W.C., Largaespada D.A., Verfaillie C.M. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002, 418:41-49.
17. Kastrinaki M.C., Pavlaki K., Batsali A.K., Kouvidi E., Mavroudi I., Pontikoglou C., Papadaki H.A. Mesenchymal stem cells in immune-mediated bone marrow failure syndromes. Clin. Dev. Immunol. 2013, 2013:265608.
18. Kemp K.C., Hows J., Donaldson C. Bone marrow-derived mesenchymal stem cells. Leuk. Lymphoma 2005, 46:1531-1544.
19. Kojima K., McQueen T., Chen Y., Jacamo R., Konopleva M., Shinojima N., Shpall E., Huang X., Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1alpha-mediated down-regulation of CXCL12. Blood 2011, 118:4431-4439.
20. Lane S.W., Scadden D.T., Gilliland D.G. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009, 114:1150-1157.
21. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
22. Le Blanc K., Samuelsson H., Gustafsson B., Remberger M., Sundberg B., Arvidson J., Ljungman P., Lonnies H., Nava S., Ringden O. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 2007, 21:1733-1738.
23. Lepperdinger G. Inflammation and mesenchymal stem cell aging. Curr. Opin. Immunol. 2011, 23:518-524.
24. Liedtke S., Biebernick S., Radke T.F., Stapelkamp D., Coenen C., Zaehres H., Fritz G., Kogler G. DNA damage response in neonatal and adult stromal cells compared with induced pluripotent stem cells. Stem Cell Transl. Med. 2015, 4:576-589.
25. Lv F.J., Tuan R.S., Cheung K.M., Leung V.Y. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells 2014, 32:1408-1419.
26. Mukherjee A., Rotwein P. Insulin-like growth factor binding protein-5 in osteogenesis: facilitator or inhibitor?. Growth Hormon. IGF Res. 2007, 17:179-185.
27. Network C.G.A.R. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 2013, 368:2059-2074.
28. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
29. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012, 10:244-258.
30. Reikvam H., Nepstad I., Tamburini J. Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity. Expert Opin. Investig. Drugs 2013, 22:1365-1370.
31. Reikvam H., Nepstad I., Bruserud O., Hatfield K.J. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget 2013, 4:830-843.
32. Reikvam H., Hatfield K.J., Ersvaer E., Hovland R., Skavland J., Gjertsen B.T., Petersen K., Bruserud O. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. Br. J. Haematol. 2012, 156:468-480.
33. Reikvam H., Olsnes A.M., Gjertsen B.T., Ersvar E., Bruserud O. Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia. Crit. Rev. Oncog. 2009, 15:1-41.
34. Rozen S., Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 2000, 132:365-386.
35. Stavrum A.K., Petersen K., Jonassen I., Dysvik B. Analysis of gene-expression data using J-Express. Curr. Protoc. Bioinformatics 2008, (Chapter 7, Unit 7.3).
36. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15545-15550.
37. Tusher V.G., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:5116-5121.
38. Uccelli A., Moretta L., Pistoia V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8:726-736.
39. Welch J.S., Ley T.J., Link D.C., Miller C.A., Larson D.E., Koboldt D.C., Wartman L.D., Lamprecht T.L., Liu F., Xia J., Kandoth C., Fulton R.S., McLellan M.D., Dooling D.J., Wallis J.W., Chen K., Harris C.C., Schmidt H.K., Kalicki-Veizer J.M., Lu C., Zhang Q., Lin L., O'Laughlin M.D., McMichael J.F., Delehaunty K.D., Fulton L.A., Magrini V.J., McGrath S.D., Demeter R.T., Vickery T.L., Hundal J., Cook L.L., Swift G.W., Reed J.P., Alldredge P.A., Wylie T.N., Walker J.R., Watson M.A., Heath S.E., Shannon W.D., Varghese N., Nagarajan R., Payton J.E., Baty J.D., Kulkarni S., Klco J.M., Tomasson M.H., Westervelt P., Walter M.J., Graubert T.A., DiPersio J.F., Ding L., Mardis E.R., Wilson R.K. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012, 150:264-278.
40. Zeytun A., Chaudhary A., Pardington P., Cary R., Gupta G. Induction of cytokines and chemokines by toll-like receptor signaling: strategies for control of inflammation. Crit. Rev. Immunol. 2010, 30:53-67.